Photo: FatCamera/Getty Images
VieCure, which makes software for oncology care, secured $43 million in funding.
Mitch Rales, cofounder of Danaher, and Northpond Ventures led the round, with significant participation from Durable Capital Partners, Socium Ventures and Sator Grove Holdings.
Rales as well as Howard "Skip" Burris III, M.D., former president of the American Society of Clinical Oncology (ASCO), joined the company’s board of directors.
WHAT IT DOES
VieCure's AI-powered offering, Halo Intelligence, gives providers a clinical inference engine as well as an oncology electronic medical record. The platform combines an individual's personal health data with digital workflows, aimed at allowing providers to design a personalized care plan.
"This milestone represents a transformative moment for VieCure and for the future of cancer care. With this $43 million investment, we’re accelerating our mission to democratize access to precision medicine in community oncology, where 80% of patients receive treatment. These funds will fuel the expansion of our AI-powered Halo Intelligence platform, which integrates real-time clinical decision support directly at the point of care, helping oncologists navigate the growing complexity of cancer treatment and deliver better outcomes at scale," Michael Power, CEO of VieCure, told MobiHealthNews.
"Announcing this at JPM, the largest healthcare investment event, underscores the urgency and opportunity in our industry. As healthcare moves beyond dated technology systems, providers need actionable intelligence at the point of care to ensure every patient, regardless of ZIP code, has access to high-quality, guideline-driven care. We’re proud to lead this charge, enabling patients to receive cutting-edge treatment close to home."
MARKET SNAPSHOT
Last year, VieCure announced a strategic partnership with Guardant Health to allow clinicians using the Halo Intelligence platform to order, track and obtain patient results of Guardant's genomic tests directly within their electronic medical record interface.
In 2024, VieCure announced the completion of a $45 million financing round led by Northpond Ventures.
Other digital health companies focused on oncology care include value-based cancer care platform Thyme Care, which last year garnered $97 million in Series D funding, bringing its total raise to $275 million.
Reimagine Care is an oncology-focused home care platform, and precision health technology company CancerIQ is focused on improving early diagnosis, treatment and prevention.
